These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Aβ seeds and prions: How close the fit? Rasmussen J; Jucker M; Walker LC Prion; 2017 Jul; 11(4):215-225. PubMed ID: 28657440 [TBL] [Abstract][Full Text] [Related]
6. A standard model of Alzheimer's disease? Walker LC; Lynn DG; Chernoff YO Prion; 2018; 12(5-6):261-265. PubMed ID: 30220236 [TBL] [Abstract][Full Text] [Related]
8. Cerebral amyloid-beta protein accumulation with aging in cotton-top tamarins: a model of early Alzheimer's disease? Lemere CA; Oh J; Stanish HA; Peng Y; Pepivani I; Fagan AM; Yamaguchi H; Westmoreland SV; Mansfield KG Rejuvenation Res; 2008 Apr; 11(2):321-32. PubMed ID: 18341428 [TBL] [Abstract][Full Text] [Related]
9. Function and toxicity of amyloid beta and recent therapeutic interventions targeting amyloid beta in Alzheimer's disease. Rajasekhar K; Chakrabarti M; Govindaraju T Chem Commun (Camb); 2015 Sep; 51(70):13434-50. PubMed ID: 26247608 [TBL] [Abstract][Full Text] [Related]
10. Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer's disease. Jackson RJ; Rudinskiy N; Herrmann AG; Croft S; Kim JM; Petrova V; Ramos-Rodriguez JJ; Pitstick R; Wegmann S; Garcia-Alloza M; Carlson GA; Hyman BT; Spires-Jones TL Eur J Neurosci; 2016 Dec; 44(12):3056-3066. PubMed ID: 27748574 [TBL] [Abstract][Full Text] [Related]
11. The participation of insulin-like growth factor-binding protein 3 released by astrocytes in the pathology of Alzheimer's disease. Watanabe K; Uemura K; Asada M; Maesako M; Akiyama H; Shimohama S; Takahashi R; Kinoshita A Mol Brain; 2015 Dec; 8(1):82. PubMed ID: 26637371 [TBL] [Abstract][Full Text] [Related]
12. [Expression of proteins related neurodegeneration in autopsy brains of the aged]. Zhu M; Meng X; Wang L; Hu Y; Zhang H; Han Z Zhonghua Bing Li Xue Za Zhi; 2014 Oct; 43(10):651-6. PubMed ID: 25567589 [TBL] [Abstract][Full Text] [Related]
13. Emerging prospects for the disease-modifying treatment of Alzheimer's disease. Walker LC; Ibegbu CC; Todd CW; Robinson HL; Jucker M; LeVine H; Gandy S Biochem Pharmacol; 2005 Apr; 69(7):1001-8. PubMed ID: 15763538 [TBL] [Abstract][Full Text] [Related]
15. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice. Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708 [TBL] [Abstract][Full Text] [Related]
16. [The pathophysiology of Alzheimer's disease with special reference to "amyloid cascade hypothesis"]. Tamaoka A Rinsho Byori; 2013 Nov; 61(11):1060-9. PubMed ID: 24450113 [TBL] [Abstract][Full Text] [Related]
17. Protein aggregation in Alzheimer's disease: Aβ and τ and their potential roles in the pathogenesis of AD. Thal DR; Fändrich M Acta Neuropathol; 2015 Feb; 129(2):163-5. PubMed ID: 25600324 [No Abstract] [Full Text] [Related]
18. Progression of Alzheimer's disease, tau propagation, and its modifiable risk factors. Takeda S Neurosci Res; 2019 Apr; 141():36-42. PubMed ID: 30120962 [TBL] [Abstract][Full Text] [Related]
19. Effect of HMG-CoA reductase inhibitors on beta-amyloid peptide levels: implications for Alzheimer's disease. Höglund K; Blennow K CNS Drugs; 2007; 21(6):449-62. PubMed ID: 17521225 [TBL] [Abstract][Full Text] [Related]
20. Plaque formation and the intraneuronal accumulation of β-amyloid in Alzheimer's disease. Takahashi RH; Nagao T; Gouras GK Pathol Int; 2017 Apr; 67(4):185-193. PubMed ID: 28261941 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]